# A Fatal Case of Acute Pulmonary Embolism after Cyanoacrylate Closure for Varicose Veins

**Authors:** Kenichi Chatani, Hiroyuki Ihori, Kazumasa Ohara, Makoto Nonomura, Tomoki Kameyama, Hiroshi Inoue

PMC · DOI: 10.3400/avd.cr.25-00113 · Annals of Vascular Diseases · 2026-03-01

## TL;DR

An elderly woman died from a severe blood clot in her lungs after a procedure to treat varicose veins, highlighting the risks and need for careful monitoring.

## Contribution

Highlights the risk of fatal pulmonary embolism after cyanoacrylate closure and emphasizes monitoring and preventive measures.

## Key findings

- Patient died from pulmonary embolism 24 days after cyanoacrylate closure for varicose veins.
- Prolonged general anesthesia and delayed thrombus formation may increase PE risk after CAC.
- Early ambulation and extended follow-up could help prevent life-threatening complications.

## Abstract

An 81-year-old female with bilateral small saphenous vein varicosities (CEAP, C2s, Ep, As, Pr) underwent cyanoacrylate closure (CAC) and stab avulsion under general anesthesia. Fourteen days later, she developed severe dyspnea and was diagnosed with pulmonary embolism (PE) and deep vein thrombosis. Despite anticoagulation, cardiopulmonary support, and catheter-directed thrombectomy, she died 24 days after admission. Adequate heparin dosing with activated partial thromboplastin time monitoring is important. Prolonged procedures under general anesthesia may increase PE risk. Early ambulation, compression therapy, and follow-up ultrasonography beyond 24 hours may help detect delayed thrombus formation and reduce life-threatening complications after CAC.

## Linked entities

- **Chemicals:** cyanoacrylate (PubChem CID 8711)
- **Diseases:** pulmonary embolism (MONDO:0005279), varicose veins (MONDO:0008638)

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, SERPINC1 (serpin family C member 1) [NCBI Gene 462] {aka AT3, AT3D, ATIII, ATIII-R2, ATIII-T1, ATIII-T2}, PROC (protein C, inactivator of coagulation factors Va and VIIIa) [NCBI Gene 5624] {aka APC, PC, PROC1, THPH3, THPH4}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, PLG (plasminogen) [NCBI Gene 5340] {aka HAE4}
- **Diseases:** type 2 diabetes mellitus (MESH:D003924), tricuspid regurgitation (MESH:D014262), right heart overload (MESH:D006333), valve insufficiency (MESH:D001022), thromboembolic complications (MESH:D013923), allergies (MESH:D004342), palpitations (MESH:D006331), vein thrombi (MESH:D000071078), septic shock (MESH:D012772), thrombophlebitis (MESH:D013924), CAC (MESH:D015812), pulmonary hypertension (MESH:D006976), sepsis (MESH:D018805), EGIT (MESH:D058545), vein thrombosis (MESH:D012170), thrombosis (MESH:D013927), death (MESH:D003643), venous thromboembolism (MESH:D054556), hypertension (MESH:D006973), cardiovascular collapse (MESH:D002318), avulsion (MESH:D000071562), DVT (MESH:D020246), right ventricular dilatation (MESH:C566255), pneumonia (MESH:D011014), hypercoagulable (MESH:D019851), stab avulsion (MESH:D051270), PE (MESH:D011655), pulmonary emboli (MESH:D020766), acute respiratory distress syndrome (MESH:D012128), venous stasis (MESH:D054070), saphenous vein varicosities (MESH:D014648), hyperlipidemia (MESH:D006949), chronic venous insufficiency (MESH:D014689), dyspnea (MESH:D004417), loss of consciousness (MESH:D014474), malignancy (MESH:D009369)
- **Chemicals:** ursodeoxycholic acid (MESH:D014580), heparin (MESH:D006493), CAC (-), lansoprazole (MESH:D064747), bezafibrate (MESH:D001629), catecholamines (MESH:D002395), oxygen (MESH:D010100), N-butylcyanoacrylate (MESH:D004659), Cyanoacrylate (MESH:D003487)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12956474/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12956474/full.md

## References

10 references — full list in the complete paper: https://tomesphere.com/paper/PMC12956474/full.md

---
Source: https://tomesphere.com/paper/PMC12956474